Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,617 across all filing types
Latest filing 2017-11-14 Annual Report
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
106年第3季財務報告書 — 201704_3164_AI1.pdf
Annual Report Classification · 100% confidence The document is titled as a "合併財務報告暨會計師查核報告" which translates to "Consolidated Financial Report and Auditor's Report" for the fiscal years 106 and 105 (Taiwanese calendar years corresponding to 2017 and 2016). It includes detailed financial statements such as consolidated balance sheets, income statements, cash flow statements, notes to financial statements, and an auditor's opinion. The presence of an auditor's report integrated with the financial statements indicates this is a full annual report document. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2017
2017-11-14 Chinese
106年第3季財務報告書 — 201703_3164_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "合併財務報告暨會計師核閱報告" which translates to "Consolidated Financial Report and Accountant's Review Report" for the third quarter of years 106 and 105 (Taiwanese calendar years corresponding to 2017 and 2016). It includes detailed financial statements such as consolidated balance sheets, income statements, equity changes, and cash flow statements, along with notes and an accountant's review report. The presence of an accountant's review report (核閱報告) indicates this is a reviewed interim financial report rather than a full annual report. The document length is about 15,000 characters, which is substantial and contains actual financial data and analysis for a period shorter than a full fiscal year (quarterly). Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2017
2017-11-14 Chinese
106年第3季財務報告書 — 201702_3164_AI1.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "合併財務報告暨會計師核閱報告" which translates to "Consolidated Financial Report and Accountant's Review Report" for the second quarter of years 106 and 105 (in the Taiwanese calendar, corresponding to 2017 and 2016). It includes detailed financial statements such as consolidated balance sheets, income statements, equity changes, and cash flow statements, along with notes to the financial statements. The presence of an accountant's review report (核閱報告) indicates this is a reviewed interim financial report rather than a full annual report. The period covered is a half-year or quarterly period, and the document contains substantive financial data and analysis. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-11-14 Chinese
106年第3季財務報告書 — 201701_3164_AI1.pdf
Regulatory Filings
2017-11-14 Chinese
106年第3季大陸投資
Regulatory Filings Classification · 95% confidence The document is a tabular disclosure of investment amounts and related financial data concerning investments in mainland China by a Taiwanese listed company. It includes details such as capital amounts, investment methods, cumulative investment amounts, and recognized investment gains or losses for the period ending in the third quarter of the 106th year (Taiwan calendar, corresponding to 2017). The document is relatively short (1404 characters) and appears to be a regulatory disclosure of investment information rather than a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion but rather specific investment data likely required by regulatory authorities. This type of document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2017-11-14 Chinese
公告本公司商標、專利及文獻授權使用合約案
Regulatory Filings Classification · 95% confidence The document is a short announcement (757 characters) from a company disclosing details about a trademark, patent, and literature licensing agreement with its subsidiary. It includes contract terms, effective dates, and impact on the company. There is no financial data, no mention of a report being attached or published, and no regulatory certification or voting results. The content is a regulatory announcement about a contract/licensing agreement, which does not fit into financial reports, earnings, management changes, or other specific categories. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2017-11-13 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.